Chloroquine
- Generic Name
- Chloroquine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3
- CAS Number
- 54-05-7
- Unique Ingredient Identifier
- 886U3H6UFF
- Background
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Chloroquine was granted FDA Approval on 31 October 1949.
- Indication
Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
Chloroquine is also used off label for the treatment of rheumatic diseases, as well as treatment and prophylaxis of Zika virus. Chloroquine is currently undergoing clinical trials for the treatment of COVID-19.
- Associated Conditions
- Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
- Associated Therapies
- -
A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Menzies School of Health Research
- Target Recruit Count
- 181
- Registration Number
- NCT02389374
The Addition of Chloroquine to Chemoradiation for Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Maastricht Radiation Oncology
- Target Recruit Count
- 13
- Registration Number
- NCT02378532
- Locations
- 🇳🇱
Maastricht Radiation Oncology, Maastricht, Netherlands
A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 60
- Registration Number
- NCT02333890
- Locations
- 🇨🇦
The Ottawa Hospital Woman's Breast Health Centre, Ottawa, Ontario, Canada
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
- Conditions
- Malaria, Vivax
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 251
- Registration Number
- NCT02216123
- Locations
- 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam
Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 16
- Registration Number
- NCT02192944
- Locations
- 🇹🇭
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
- Conditions
- Plasmodium Vivax InfectionPlasmodium Vivax Clinical EpisodePlasmodium Falciparum InfectionPlasmodium Falciparum Clinical Episode
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- Papua New Guinea Institute of Medical Research
- Target Recruit Count
- 524
- Registration Number
- NCT02143934
- Locations
- 🇵🇬
PNG Institute of Medical Research, Maprik, East Sepik Province, Papua New Guinea
Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis
- Conditions
- Malaria
- Interventions
- Biological: CPS-immunizationBiological: Controlled Human Malaria InfectionDrug: chloroquineDrug: atovaquone/proguanil
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT02080026
- Locations
- 🇳🇱
Radboud university medical center, Nijmegen, Gelderland, Netherlands
Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
- Conditions
- Solid TumorsMalignant Neoplasm
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 24
- Registration Number
- NCT02071537
- Locations
- 🇺🇸
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT02058173
- Locations
- 🇮🇷
Health Policy Research Center, Shiraz, Fars, Iran, Islamic Republic of
Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 119
- Registration Number
- NCT02043652
- Locations
- 🇧🇷
Hospital do Jurua, Cruzeiro do Sul, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.